Prof. Shengyu Zhou 周生余
Chief Physician, Professor
Hematologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and immunotherapy for lung cancer, malignant lymphoma, head and neck cancers, and brain metastases.
Dr. Zhou graduated from Hunan Medical University in 1993 and earned a doctorate in oncology from Peking Union Medical College in 2006. With over 20 years in medical oncology, Dr. Zhou focuses on basic and clinical research in malignant lymphoma. Dr. Zhou has participated in multiple new drug clinical trials and national research projects, published over 10 academic papers, and contributed to textbooks on medical oncology, lymphoma, and lung cancer.
Professional roles
- Standing Committee Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Member, Targeted Therapy Professional Committee, China Anti-Cancer Association
- Director, Beijing Cancer Prevention and Control Society
- Designated Chair, Lymphoma Immunotherapy Professional Committee, Beijing Cancer Prevention and Control Society
Name order: in Chinese the family name comes first (Zhou Shengyu). Papers usually list the name as Shengyu Zhou or Zhou S.
Selected publications
70 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Exp Hematol Oncol, 2026 (first author): Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study. PubMed 42351304
- Transl Androl Urol, 2020 (first author): Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with lung metastasis: a case report and literature review. PubMed 33457258
- Asia Pac J Clin Oncol, 2019 (first author): Clinicopathologic characteristics and outcome of patients with different EGFR mutations. PubMed 30311393
- Thorac Cancer, 2018 (first author): Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. PubMed 30152052
- Int J Clin Exp Pathol, 2018 (senior author): Serum EGFR gene mutation status via second-generation sequencing and clinical features of patients with advanced lung cancer. PubMed 31949733
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion